Related Experiment Videos
Human lymphokine-activated killer cells develop syngeneic killing ability
G Gallagher1, J Findlay, F A al-Azzawi
1Department of Obstetrics and Gynaecology, University of Cambridge, Addenbrooke's Hospital.
Abstract:
Lymphokine-activated killer (LAK)-cell therapy has emerged as a new strategy in designing protocols for the treatment of cancer. However, in its present clinical form, it has not fulfilled the early promise shown in murine models of human metastatic disease. In an attempt to gain understanding as to why this might be the case, we measured the ability of human LAK cells, generated in vitro for 4 days, to kill LAK cells from the same donor that had been exposed to IL-2 in vitro for 8 days, and vice versa. In eight separate experiments using different donors, 4-day ('early') LAK cells were able to kill syngeneic 8-day ('late') LAK cells, while late LAK cells were also able to kill early LAK cells. Strong killing was observed in both directions, which was almost total in one instance. In order to assess the development of this phenomenon, early LAK cells were tested for their ability to kill syngeneic LAK cells that were 1, 2, 3 or 4 days 'older' and the reciprocal experiment conducted using late LAK cells as effectors. The results illustrate a strong capacity for the development of syngeneic killing by human LAK cells. The possible implications of this phenomenon for the clinical administration of LAK cell/IL-2 therapy are discussed.
Insights
Human Lymphokine-Activated Killer (LAK) cells can kill other LAK cells from the same donor, a phenomenon that may impact cancer treatment effectiveness. This syngeneic killing capacity develops over time, influencing LAK cell/IL-2 therapy protocols.
Area of Science:
- Immunology
- Cancer Therapy
- Cell Biology
Background:
- Lymphokine-activated killer (LAK)-cell therapy shows promise for cancer treatment but has clinical limitations.
- Understanding LAK cell behavior is crucial for optimizing therapeutic strategies.
Purpose of the Study:
- To investigate the phenomenon of syngeneic killing among human LAK cells.
- To assess the development of this killing capacity over time.
Main Methods:
- Human LAK cells were generated in vitro for varying durations (4 days vs. 8 days).
- The cytotoxic activity of 'early' LAK cells against 'late' LAK cells, and vice versa, was measured.
- Syngeneic killing was assessed using LAK cells of different maturation stages (1-4 days difference).
Main Results:
- Both 4-day ('early') and 8-day ('late') human LAK cells demonstrated the ability to kill syngeneic LAK cells.
- Strong cytotoxic activity was observed in both effector-target cell combinations.
- The capacity for syngeneic killing by human LAK cells was found to be significant and develops with maturation.
Conclusions:
- Human LAK cells possess a notable capacity for syngeneic killing.
- This phenomenon has potential implications for the clinical efficacy and administration of LAK cell/IL-2 therapy.
- Further research is needed to understand and potentially leverage this self-killing behavior in cancer treatment.